Abstract
Cerebral small vessel disease (CSVD) represents a diverse cluster of cerebrovascular diseases primarily affecting small arteries, capillaries, arterioles and venules. The diagnosis of CSVD relies on the identification of small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, and microbleeds using neuroimaging. CSVD is observed in 25% of strokes worldwide and is the most common pathology of cognitive decline and dementia in the elderly. Still, due to the poor understanding of pathophysiology in CSVD, there is not an effective preventative or therapeutic approach for CSVD. The most widely accepted approach to CSVD treatment is to mitigate vascular risk factors and adopt a healthier lifestyle. Thus, a deeper understanding of pathogenesis may foster more specific therapies. Here, we review the underlying mechanisms of pathological characteristics in CSVD development, with a focus on endothelial dysfunction, blood-brain barrier impairment and white matter change. We also describe inflammation in CSVD, whose role in contributing to CSVD pathology is gaining interest. Finally, we update the current treatments and preventative measures of CSVD, as well as discuss potential targets and novel strategies for CSVD treatment.
Introduction
Cerebral small vessel disease (CSVD) refers to a disorder of perforating cerebral arterioles, capillaries, and venules (Wardlaw et al., 2013b). Typical magnetic resonance imaging (MRI) markers of CSVD in the brain include white matter hyperintensities (WMHs), lacunes, microbleeds, enlarged perivascular spaces, and subcortical infarcts (Wardlaw et al., 2013c). CSVD was once thought to be innocuous with clinically silent manifestations, but is now recognized as a major risk factor for stroke, present in about a quarter of ischemic strokes and most hemorrhagic strokes (Kapasi et al., 2017; Wardlaw et al., 2019). CSVD is also associated with gait problems and mood disturbances in older people (Choi et al., 2012; Wardlaw et al., 2013c). Furthermore, CSVD has become the leading vascular contributor to cognitive impairment and dementia worldwide, posing a massive burden to societies and health-care systems world-wide facing increased life expectancies and a more aged population (Gorelick et al., 2011).
Although the importance of and concern regarding CSVD is clearly recognized, there is a lack of effective prophylactic or therapeutic regimens. The current approach is management of vascular risk factors associated with CSVD including hypertension, smoking, diabetes, and hypercholesterolemia (Wardlaw et al., 2014, 2019). In fact, the failure in achieving a breakthrough for CSVD treatment is primarily due to a poor understanding of its etiology. Initially, a compromised blood-brain barrier (BBB) integrity was postulated to create both microbleeds and reduced blood flow distally that would induce ischemia and the subcortical infarcts (Wardlaw et al., 2003). These ischemic changes may in turn lead to the loss of oligodendrocytes, contributing to the impaired myelination in CSVD (Peters, 2007), which corresponds to the WMHs on MR images. However, a subsequent study suggested that endothelial dysfunction is the key initiator for CSVD and its pathogenesis, predating BBB breakdown (Rajani et al., 2018). Recently, the contribution of inflammation to CSVD has attracted increasing attention and an emerging concept of “inflammaging” referring to the chronic, sterile, low-grade inflammation observed in older organisms and humans, and brain inflammaging was proposed as an etiological factor for CSVD (Li T. et al., 2020).
Given the multifactorial and complex nature of CSVD, a better understanding of its pathogenesis would aid in the successful development of specific and effective interventions for CSVD. Hence, in this review we will integrate the pathophysiological events of the endothelium, smooth muscle cells, BBB, neural cells and inflammation and provide their possible linkages for more insight into CSVD pathogenesis. In addition, we will discuss the current treatments as well as potential targets to prevent and repair or even reverse the brain damage in CSVD.
Mechanistic insights into pathological alterations in cerebral small vessel disease
Endothelial dysfunction
Endothelial cells (ECs) serve as a functional and structural barrier between tissue and blood, modulating blood flow, regulating transport of circulating components and participating in inflammatory processes. In the brain tissue, ECs have an additional role as a vital part of the BBB and the neurovascular unit (NVU) (Figure 1). Therefore, the alteration of ECs in function or quantity was initially believed to be an etiological contributor to CSVD. Several studies have revealed that brain ECs remain microscopically intact and that cellular loss is not observed even in cases with severe CSVD (Lammie, 2002; Craggs et al., 2013; Hainsworth et al., 2015). More recently, increasing evidence has emerged suggesting that endothelial dysfunction may initiate pathological changes, both in genetic and sporadic CSVD (Quick et al., 2021).
FIGURE 1
The Neurovascular Unit (NVU). Vascular (endothelial cells and pericytes) and brain (astrocytes, oligodendrocytes, and neurons) cells interact and function as a unit, millions of which reside in the brain. Figure created using BioRender.com.
Endothelial dysfunction-induced brain damage manifests in several ways via different mechanisms (Figure 2). In CSVD patients, both impairment and autoregulation of cerebral blood flow (CBF) were observed using positron emission tomography (PET) and MRI, respectively (Poggesi et al., 2016). ECs are undeniably involved in this pathological change as one of the primary roles of ECs is to regulate the vascular tone of the vessel wall in cerebral arteries and microvessels. EC-derived nitric oxide (NO) is an important signaling molecule for local CBF regulation that mediates vessel dilation in response to external stimuli (Katusic and Austin, 2014; Hu et al., 2017; De Silva and Faraci, 2020). Reduced release of NO is an established metric for detecting endothelial dysfunction, as its occurrence has been reported to result in pathological vasoconstriction, compromised CBF, and ultimately, tissue ischemia (Gunarathne et al., 2009; Quick et al., 2021). The bioavailability of NO can be experimentally measured using the Griess reaction; however, a clinically relevant version of this method is not yet available. In patients, the relative change in reflective index (ΔRI%) upon administration of an NO-releasing β2-andrenergic receptor stimulant agent such as Salbutamol can be used to evaluate endothelial function (Gunarathne et al., 2009). The level of endothelial NO synthase (eNOS), an enzyme that converts L-arginine to NO, can be used to evaluate the production of NO as well. Studies in CSVD animal models and of the cerebrospinal fluid (CSF) of CSVD patients have reported reduced eNOS, indicating EC dysfunction (Quick et al., 2021). Additionally, vascular risk factors such as aging and hypertension, can raise the level of reactive oxygen species, driving eNOS to produce the destructive superoxide anion (O2–), which in turn further degrades bioavailability of NO (Villamor et al., 2003; De Silva and Faraci, 2020). Endothelin-1 (ET1) is an important regulating factor for maintaining homeostasis in the vessel, which can act on smooth muscle cells to cause vasoconstriction, but also can stimulate adjacent ECs to produce NO to cause vasodilation (Houde et al., 2016). EC dysfunction results in elevated ET1 in plasma and disrupts the balance between NO and ET1, making ET1 another contributor to the pathological vasoconstriction (Galatius et al., 1999; Quick et al., 2021).
FIGURE 2
Pathological characteristics of cerebral small vessel disease (CSVD). Of them, decreased nitric oxide (NO) bioavailability is the most commonly used marker of dysfunction in endothelial cells (ECs). Reducing NO levels can lead to less vasodilation of neighboring smooth muscle cells, which in turn causes nitrosylation or nitrosation of tight junction (TJ) proteins, ultimately resulting in BBB disruption. Increased ET1 release by dysfunctional ECs can give rise to pathological vasoconstriction. The reduction of semaphorin 3G and sirt1 due to endothelial dysfunction can affect synaptic plasticity and BBB integrity respectively, and consequently, contribute to cognitive decline. Additionally, the factors secreted by dysfunctional ECs such as von Willebrand factor (vWF), heat shock protein 90α (HSP 90α), acid sphingomyelinase (ASM) and matrix metalloproteinases (MMPs) can induce vessel damage directly, as well as impair the integrity of the BBB and white matter. Compromising the BBB allows for entry of potential detrimental plasma components and immune cells into the brain parenchyma, further promoting BBB breakdown and white mater damage via neuroinflammation and direct neurotoxic effects. Figure created using BioRender.com.
Semaphorin 3G, a recently characterized member of the class 3 secreted semaphorin subfamily, is heavily expressed in ECs, but not in neuronal or glial cells. It has been shown that Semaphorin 3G is an endothelium-derived synaptic organizer, whose loss in ECs resulted in behavioral and memory deficits (Zhang et al., 2014; Tan et al., 2019). This study demonstrated a critical role for semaphorin 3G in regulating synaptic function in the hippocampus via the Nrp2/PlexinA4 signaling cascade as well (Tan et al., 2019). Thus, it is speculated that ECs dysfunction may promote cognitive decline in CSVD via non-vascular effects on synaptic organization, in addition to vascular effects on CBF. When these effects are considered with its roles in maintaining the integrity of BBB and myelin (described in detail in the subsequent section), the magnitude of the potential impact of cerebral ECs on the pathological aetiology of CSVD can be fully appreciated. As for the causes of endothelial dysfunction, aging is the greatest risk factor for CSVD and a major contributor to endothelial dysfunction through several pathways involving adaptor protein p66Shc, oxidative stress described more thoroughly elsewhere (De Silva and Faraci, 2020). Additionally, the linkage between endothelial dysfunction and another important risk factor for CSVD, hypertension, is also established (Dharmashankar and Widlansky, 2010), involving excessive vascular oxidative stress, vascular inflammation and reduced prostaglandins productions (Dharmashankar and Widlansky, 2010; Cipolla et al., 2018).
Blood-brain barrier breakdown
The BBB is primarily composed of ECs, the TJs between ECs, the basement membrane, astrocytic end-foot processes, and pericytes. It tightly regulates the movement of ions, molecules and cells to and from the circulating blood and the CSF or brain parenchyma, ensuring proper neuronal function as well as protecting the brain from harmful substances and pathogens. A breakdown of the BBB permits the extravasation of fluids and other plasma constituents, causing an enlargement of the perivascular space, localized damage to brain parenchyma such as cerebral microbleeds, and white matter changes (Hartz et al., 2012; Wardlaw et al., 2013b; Ihara and Yamamoto, 2016). Furthermore, the impairment might also increase the interstitial fluid volume and thicken and/or stiffen arteriole walls, exacerbating their vasodilatation and further compromising transport of oxygen and nutrient (Wardlaw et al., 2019). Evidence that impairment of BBB is a key contributing component of CSVD pathogenesis is accumulating (Wardlaw, 2010). In autopsy studies oedemas were observed in white matter lesions, indicating fluid leakage due to impaired BBB (Feigin and Popoff, 1963; Black et al., 2009). This result was corroborated by a study that used albumin extravasation to evaluate BBB integrity, wherein widespread leakage was found in the aging brain and accumulated in severe white-matter lesions (Simpson et al., 2007). Recently, dynamic contrast-enhanced (DCE)-MRI has emerged as a novel tool to quantitatively evaluate BBB permeability in patients. Using the DCE-MRI method, multiple studies revealed that BBB integrity was disrupted in CSVD patients and that the extent of increased BBB permeability was associated with a higher white matter hyperintensity burden as well as cognitive decline (Munoz Maniega et al., 2017; Zhang et al., 2017; Li Y. et al., 2018; Walsh et al., 2021). Similarly, a longitudinal study investigated by Wardlaw et al. (2013a) revealed a significant correlation between poor functional outcome and increased BBB permeability in CSVD patients.
With regard to possible causes of BBB disruption in CSVD, several potential mechanisms have been proposed (Figure 2). The formation and maintenance of TJ proteins claudin-5 and occludin, which are expressed by ECs, are vital to the integrity of the BBB. An in vitro study showed ECs dysfunction resulted in a reduction of claudin-5 expression and in animal models and patients with CSVD, and EC dysfunction corresponded to BBB breaches (Nitta et al., 2003; Bailey et al., 2011; Rajani et al., 2018). ECs dysfunction may also promote the degradation of the TJ proteins by releasing MMP such as MMP-2 and MMP-9 (Yong et al., 2001; Gheissari et al., 2018; Loso et al., 2018). Using rat models of CSVD, one study found an increase in expression of MMP-2 and MMP-9, and consequently, a decrease in claudin-5 and occludin, which was mitigated with treatment of MMP inhibitors (Yang et al., 2007). In addition, oxidative stress (i.e., increased reactive oxygen species) due to aging and hypertension in CSVD are considered major risk factors of BBB failure as it reduces NO bioavailability, resulting in a loss of TJ proteins (De Silva and Miller, 2016). Recent studies have presented other potential mechanisms that give rise to BBB dysfunction with aging. Acid sphingomyelinase (ASM) is a sphingolipid metabolizing enzyme, primarily derived from ECs in brain. Park et al. (2018) found increased ASM is a critical factor for BBB disruption. Genetic inhibition and endothelial-specific knockdown of ASM in mice ameliorated BBB breakdown. In contrast, overexpress of ASM in brain ECs accelerated BBB impairment and neurodegenerative change, suggesting a novel role for ASM in neurovascular function in aging (Park et al., 2018). The study also revealed that the increased permeability of the BBB associated with ASM expression is due to increased caveolae-mediated transcytosis, without detectable change in TJ proteins (Park et al., 2018). Transcriptional regulator sirtuin 1 is associated with endothelial dysfunction in aging. The declined expression of sirtuin 1 is linked to changes in permeability of the BBB in a study reported by Stamatovic et al. (Stamatovic et al., 2019). Conversely, the increased expression of sirtuin 1 protects against BBB impairment in aged transgenic mice (Stamatovic et al., 2019). The mechanism underlying sirtuin 1-meaiated BBB integrity is associated with stabilization claudin-5/ZO-1 interactions and the level of claudin-5 expression (Stamatovic et al., 2019). More recently, in a rat model of chronic cerebral hypoperfusion representing CSVD, Sun et al. found pericyte loss in the brain associated with the BBB impairment (Sun et al., 2021).
White matter damage
WMH is a hallmark feature of human CSVD, predominantly observed around the ventricles and subcortically. The prevalence of WMH in MR images increases from about 5% for people aged 50 years to nearly 100% for people aged 90 years (Wardlaw, 2001). WMH is a well-established marker for predicting gait dysfunction via disruption of network and cortical thinning (de Laat et al., 2011; Kim et al., 2016). A wide range of evidence revealed WMH is associated with worse cognitive performance in CSVD (Debette and Markus, 2010; van der Holst et al., 2018; Jiang J. et al., 2022) and is due to disrupted structural and functional connectivity, as well as changes in cortical thickness at multiple cognitive domains (Righart et al., 2013; Tuladhar et al., 2015; Ter Telgte et al., 2018). Pathological changes of WMH are associated with several aspects of white matter damage including demyelination, loss of oligodendrocytes and axonal damage (Gouw et al., 2011). Both hypoperfusion and BBB impairment have been suggested as causes of WMH.
Compelling studies have observed hypoperfusion in the WMH using PET and MRI, likely resulting from vascular pathology involving multiple small arterioles (Moody et al., 1997; Markus et al., 2000; Thal et al., 2003; Makedonov et al., 2013; Wong et al., 2019). Interestingly, a comparative study found low CBF in normal-appearing white matter as well, to a lesser extent than that in the regions of WMH (O’Sullivan et al., 2002). Consistent with these findings, Promjunyakul et al. (2018) recently reported normal-appearing white matter with low CBF becoming abnormal at follow-up. The investigation also used diffusion tensor imaging (DTI) to evaluate the structural integrity of white matter. They concluded that CBF and DTI metrics were able to independently predict WMH growth and that WMH progression is likely due to demyelinating injury, secondary to insufficient perfusion (Promjunyakul et al., 2018). Although the etiology of impaired CBF in white matter still remains incomplete and unclear, ECs dysfunction-mediated pathological vasodilation is considered a pivotal contributor as we discussed earlier. More recently, a study using stroke-prone spontaneously hypertensive rat (SHR-SP) as a CSVD model showed that dysfunctional ECs secrete HSP 90α, which impeded oligodendroglial differentiation, thereby impairing myelination and myelin repair (Rajani et al., 2018). The authors also revealed that restoring EC function was able to reverse the oligodendroglia pathologies. Thus, this evidence supports EC dysfunction as one of the determinant contributors to white matter damage via vascular and non-vascular effects.
A compromised BBB is another pathology linked to the development of WMH (Figure 2). In an MRI study, BBB breakdown in the WMH was worse than that in the normal-appearing white matter and gray matter, evidenced by higher leakage rates and volumes (Wong et al., 2019). BBB impairment was aggravated in proximity to WMH. This finding supports previous studies in which an increase in BBB permeability near the WMH was found, implying that the BBB in normal appearing white matter is increasingly impaired in proximity to WMH (Huisa et al., 2015; Wardlaw et al., 2016; Munoz Maniega et al., 2017). Furthermore, it has been reported that MRI diffusivity is able to discriminate WMH from normal-appearing white matter, including mild WMH (Ihara and Yamamoto, 2016). Thus, BBB impairment might be an early predictor of white matter damage, occurring prior to the formation of WMH. Several hypotheses have been raised concerning the white matter damage resulting from leaky BBB. The impaired BBB may cause an increase in interstitial fluid and the resulting perivascular edema can intoxicate brain cells (Li Q. et al., 2018). Additionally, BBB breakdown allows for the entry of potentially harmful toxins and immune cells into the brain, which may directly cause deleterious effects (Sweeney et al., 2018). The leaky constituents can indirectly cause brain injury as well. For instance, the extravasated fibrinogen obstructs the maturation of oligodendrocyte precursor cells, thereby inhibiting myelin maintenance and repair (Wardlaw et al., 2019). Fibrin cleaved from fibrinogen is able to trigger local neuroinflammation by activating microglia and recruiting peripheral macrophages, cells known to contribute to the progression of demyelination (Petersen et al., 2018; Sweeney et al., 2018). Although evidence supports BBB breakdown playing a pivotal role in WMH formation, it is important to note that the BBB can remain intact in patients with WMHs, as exemplified by Rajani et al. (2019). Likewise, Hainsworth et al. (2017) corroborated a lack of direct association of BBB dysfunction with white matter abnormalities. Therefore, further research in this area is required to elucidate this important relationship.
Inflammation
There is growing interest in exploring the relationship between inflammation and CSVD. Based on circulating biomarkers, CSVD inflammation is classified as either systemic inflammation (e.g., C-reactive protein, interleukin-6) or vascular inflammation (e.g., homocysteine, vWF) (Poggesi et al., 2016; Low et al., 2019). Interestingly, regional analysis showed vascular and systemic inflammation appears to correspond to two subtypes of CSVD with different site preferences (Low et al., 2019). Vascular inflammation is associated with the formation of CSVD in brain regions supplied by deep perforator arteriopathy (DPA) (e.g., basal ganglia) (Low et al., 2019; Li T. et al., 2020), while systemic inflammation is often linked to cerebral amyloid angiopathy (CAA)-related vascular injury in brain regions supplied by cortical and leptomeningeal vessels (Low et al., 2019; Li T. et al., 2020). One possible explanation for the differential vulnerability to vascular damage is due to distinct features of the cerebrovascular network in certain regions (Low et al., 2019). Although the link between CSVD subtype and inflammation classification is unclear, evidence supports inflammation’s involvement in critical pathophysiological mechanisms of endothelial dysfunction and BBB disruption. In the spontaneously hypertensive rat (SHR) CSVD animal model, Kaiser et al. (2014) showed peripheral immune cell (e.g., T cells, NK cells) migration and microglial activation (e.g., IL-1β secretion), in conjunction with inflammation, endothelial dysfunction and BBB disruption. In the same CSVD model, Zhang et al. (2019). observed cognitive function of the SHR animals concomitantly with a high expression of Toll-like receptor 4 (TLR4) in the hippocampus, which is a key signal transduce to trigger inflammatory responses. Consistently, Gao et al. (2019) not only confirmed the high expression of TLR4 in hippocampus but also glial (microglia and astrocyte) activation and evaluated level of IL-1β and TNF-α. The study also found white matter degeneration in corpus callosum and external capsule of SHR. In the SHR-SP model, Jalal et al. (2015) reported infiltrating T cells and neutrophils appeared around endothelial cells and BBB leakage was observed subsequently. The animals exhibited extensive white matter abnormalities and behavioral decline, which were effectively restored by treatment with anti-inflammatory agent minocycline. Brain-gut axis refers to the bidirectional signaling between the gastrointestinal tract, or gut microbiota, and the brain (Dinan and Cryan, 2017). The axis has gained growing interest in recent years for its role in maintaining homeostasis. Accumulating evidence suggest a link between the gut microbiome and the development of cardiovascular diseases and neurodegenerative disorders (Karlsson et al., 2012; Friedland, 2015; Durgan et al., 2019; Sanchez-Rodriguez et al., 2020). Using SHR-SP model, James et al. (Nelson et al., 2021). provided direct evidence that the gut microbiome involved in the onset or progression of CSVD via influencing the integrity of BBB. The possible mechanism is that microbiome enhanced inflammation in the gut, which may become systemic, eventually inducing neuroinflammation via the brain-gut axis. A medical research council cognitive function and aging study also revealed the elevation of inflammatory markers in close proximity to diseased arteries accompanied by BBB dysfunction (Wharton et al., 2015). A more recent clinical study found an association between neutrophil count and CSVD, especially in enlarged perivascular spaces within the basal ganglia and in lacunes, supporting its value for predicting the presence of CSVD (Jiang L. et al., 2022). Possible mechanisms of inflammation in CSVD development include in endothelial dysfunction, white matter lesions and BBB disruption (Jiang L. et al., 2022). The relationship between inflammation and BBB impairment is well-documented; however, the direction of causality remains debatable. Several studies suggest that BBB damage precedes inflammation, enabling entry of detrimental plasma components and immune cells (Petersen et al., 2018; Sweeney et al., 2018). Others believe that inflammation compromises BBB integrity, which can be preserved by pharmacologically blocking the inflammation (Abbott, 2000; Yenari et al., 2006; Rouhl et al., 2012; Kerkhofs et al., 2020). More recently, Walsh et al. (2021), using PET imaging of the translocator protein 11C-PK11195, found both microglial activation and increased BBB permeability occurred in sporadic CSVD, but they were spatially distinct processes. A possible explanation for this finding is that these two processes might occur independently of each other (Edison, 2021). Thus, to reveal the sequence of BBB and inflammation in CSVD, longitudinal studies with multiple time points would be valuable.
Other potential risk factors of CSVD inflammation have gained attention as well (Figure 3). Hypertension and advanced age are well-known epidemiologic risk factors for CSVD (Schreiber et al., 2020). They are the major contributors to the pathologic changes of cerebral small vessels, characterized by loss of smooth muscle cells from the tunica media, deposits of fibro-hyaline material, narrowing of the lumen, and thickening of the vessel wall (Pantoni, 2010). Ultimately, the vascular remodeling/injury led to impaired CBF regulation and subsequent hypoxia and ischemia of local brain parenchyma (Evans et al., 2021). These histopathological changes are recognized features of CSVD development. In addition to inducing vascular alterations, hypertension and aging can also cause endothelial dysfunction, BBB breakdown in CSVD as described in previous sections. Recently, hypertension has been proposed to trigger low grade systemic and vascular inflammation as well as activation of microglia, both which are also associated with CSVD (Petrie et al., 2018; Evans et al., 2021). Age-related inflammation, termed inflammaging, is an emerging concept that refers to the status of chronic, sterile, low-grade inflammation in older organisms, resulting from cellular senescence, immunosenescence, mitochondrial dysfunction, defective autophagy, and metaflammation (Franceschi et al., 2000; Vitale et al., 2013). Inflammaging is increasingly considered a risk factor for CSVD, especially for age-related CSVD. A recent review from Li T. et al. (2020) proposed inflammaging might contribute to CSVD progression by inducing systemic and vascular inflammation. They suggested multiple inflammatory mediators such as tumor necrosis factor (TNF), caspase-1, IL-1β, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome are produced during inflammaging, thereby resulting in BBB leakage and endothelial dysfunction.
FIGURE 3
Contributions of inflammation to cerebral small vessel disease (CSVD). Chronic hypertension-induced vascular remolding leads to hypoxia and ischemia of local brain parenchyma, thereby triggering activation of microglia. In addition, hypertension and aging can generate chronic, low-grade inflammation. The inflammatory molecules generated and immune cells recruited as a result contribute to BBB impairment and endothelial dysfunction. Figure created using BioRender.com.
Degeneration of smooth muscle cells
In CSVD, progressive degeneration and loss of smooth muscle cells are characteristic alterations that contribute to the vascular remodeling and the subsequently impaired regulation of CBF (Frosen and Joutel, 2018; Evans et al., 2021). Remodeling is often coupled with infiltration of plasma components or lipids in the vessel wall, which may further exacerbate vascular alteration and dysfunction. It has been reported that macrophages infiltrating vascular walls produce reactive oxygen species, provoke the hypertrophy of smooth muscle cells, and secrete MMPs (Virdis et al., 2004). Additionally, the infiltrating fibrinogen is able to inhibit the expression of peroxisome proliferators-activated receptors in smooth muscle cells, resulting in an increased expression of C-reactive protein and MMP-9 and an accelerated progression of atherosclerotic plaques (Wang et al., 2015). In mature arteries, smooth muscle cells maintain contractile phenotype with a low synthetic activity. In response to local environmental changes from injury or hypertension, the cells can convert to synthetic phenotype with decreased contractility and increased proliferation. This phenotypic conversion of smooth muscle cells was recently considered another pathological character of vascular remodeling in CSVD. Liu et al. (2021) using the SHR CSVD model revealed that smooth muscle cells in cerebral small arteries shifted from the contractile phenotype to synthetic phenotype during the chronic process of hypertension and aging. Li C. C. et al. (2020) successfully established a mouse CSVD model using angiotensin II, wherein BBB dysfunction, white matter damage and cerebral vascular remodeling (e.g., thickening of vascular wall) were found. The study also observed low expression of the contractile type marker α-smooth muscle actin (α-SMA) and high expression of high expression of the synthetic phenotype marker proliferating cell nuclear antigen (PCNA), indicating the phenotypic conversion of smooth muscle cells. The exact mechanism of smooth muscle cells degeneration is not yet well understood. It has been showed that amyloid ß (Aß) peptide deposition might be responsible in CAA (Frosen and Joutel, 2018). Interestingly, in SHR-SP, impaired Aß clearance was observed as well (Held et al., 2017), implicating a role in smooth muscle cells degeneration in non-amyloid CSVD. Nevertheless, future studies are required to elucidate the mechanisms of smooth muscle cells degeneration at in CSVD.
Prevention and treatment for cerebral small vessel disease
Prevention and treatment of CSVD include lifestyle modifications such as smoking and pharmacologic interventions. Antiplatelet, anti-hypertensive and statin therapies are standard pharmacologic treatments (Cannistraro et al., 2019). Anti-platelets are generally used for ischemia stroke. A pooled analysis of randomized trials has shown that antiplatelet therapy such as aspirin after acute subcortical infarction reduces the risk of recurrent stroke by 30% (Kwok et al., 2015). A meta-analysis of four trials (ACCORD-MIND, PRoFESS, PROGRESS, and SCOPE) showed that intensive antihypertensive medication resulted in significantly less progression of WMH compared to guidelines for blood pressure reduction (van Middelaar et al., 2018). Statins are another evidence-based therapy for CSVD. Less WMH progression in patients who took low dose rosuvastatin than in control, suggesting statin might delay WMH progression (Ji et al., 2018). Another randomized controlled trial found low-dose statins before stroke reduced post-stroke WMH progression (Xiong et al., 2014). However, data from Prevention of Decline in Cognition after Stroke Trial (PODCAST) showed that neither intensive lipid-lowering nor blood pressure ameliorated the cognitive decline after stroke delay (Bath et al., 2017). Apparently, standard pharmacologic treatments are beneficial for CSVD treatment, but their efficacy is limited. Encouragingly, with improved understanding of the pathogenesis of CSVD, novel therapeutic interventions have been proposed. In an animal study, cilostazol, a phosphodiesterase inhibitor, reduced cognitive decline and ameliorated gliovascular damage via endothelial stabilization (Kitamura et al., 2017). The lacunar intervention (LACI-1 and LACI-2) Trials testing cilostazol for CSVD are ongoing (Blair et al., 2019; Wardlaw et al., 2020). Minocycline is an anti-inflammatory drug with multiple immune-modulating properties with promising clinical data for multiple sclerosis (Brundula et al., 2002; Metz et al., 2017). In CSVD models, Jalal et al. (2012, 2015) showed minocycline decreased neuroinflammation, alleviated white matter damage, improved behavioral performance, and prolonged life expectancy. Several other anti-inflammatory drugs including fingolimod, natalizumab and rituximab have been utilized to treat neuroinflammatory diseases and they are expected to be potent candidates for CSVD treatment (Fu and Yan, 2018).
Cell therapy is widely viewed as a promising strategy for treatment of neurological disorders. Currently, there is a considerable interest in stem-cell therapy for CSVD treatment. Nakazaki et al. (2019) reported the first study investigating the therapeutic potential of mesenchymal stem cells (MSCs) for improving cognitive impairment in a CSVD model of SHR. The study revealed that intravenously infused MSCs restored BBB function by remodeling the microvasculature and inhibited progressive brain atrophy by reducing Aβ accumulation. As a result, improved cognitive function was achieved in the animals. Transplantation of MSCs was also found to increase the density of the pial microvascular network in the SHR brain, reaching a similar level as young Wistar-Kyoto rats (Sokolova et al., 2017). This finding implies that MSCs may have the potential to improve hypoperfusion resulting from the low CBF in CSVD. Given the above-mentioned contributions of white matter damage to CSVD development, white matter might be a compelling therapeutic target. In fact, several stem cell populations capable of differentiating into oligodendrocytes, e.g., oligodendrocyte progenitor cells and glial-restricted progenitors (GRPs), have been found to myelinate in the adult brain, resulting in both structural repair and functional restoration of damaged white matter (Piao et al., 2015; Li S. et al., 2019; Wang et al., 2021). Thus, transplantation of myelinated stem cells for CSVD treatment is worth evaluation in future research.
Conclusion
Cerebral small vessel disease is an important pathology of stroke, age-related cognitive decline, accounting for about half of all dementias. Controlling traditional risk factors via pharmacologic treatments and lifestyle modification are the current approaches for prevention and therapy of CSVD, particularly for patients with clinical presentations. Covert cerebral small vessel disease (ccSVD) is detectable on neuroimages lacking overt neurological manifestations, is highly prevalent in aging population and increases the risk of future stroke, dementia or death (Wardlaw et al., 2021; Bordes et al., 2022). A recent guideline released from European Stroke Organization (ESO) suggested that antiplatelet drugs such as aspirin are not recommended and little evidence is found for lipid lowering in ccSVD (Wardlaw et al., 2021). Thus, there is an urgent need to explore novel avenues to stop the development and clinical diseases resulting from ccSVD. The incomplete understanding of pathogenesis is a major reason for the lack of more specific preventive and therapeutic strategies for CSVD. Encouragingly, accumulating evidence supports pathophysiological changes such as endothelial dysfunction, white matter abnormality, and BBB impairment, as well as inflammation, are responsible for CSVD etiology. Such advancements in the understanding of CSVD has provided targets for potential CSVD remedies. Studies targeting endothelia and inflammation have obtained positive results in experimental studies. For exploring more potential targets and hastening their clinical translation, many questions remain to be addressed in future studies, for instance the order of and interactions between these pathological changes. Additionally, the initiator of CSVD presence is still unclear, whose identification might allow the possibility for a reversal in the earliest stages.
Statements
Author contributions
YG, DL, DC, JL, JM, SL, and CC conceived and designed the manuscript. YG, AT, and CC wrote the main manuscript and revised the manuscript. All authors reviewed the manuscript, read and approved the final manuscript.
Funding
This work was supported by the Fund Project of Central Government for Guiding Development of the Local Science and Technology (Free exploration for basic research), Dalian Municipal Medicine and Science Planning Project (2011005), and Dalian Municipal Medical Key Specialty Climbing Project (2022ZZ215).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abbott N. J. (2000). Inflammatory mediators and modulation of blood-brain barrier permeability.Cell Mol. Neurobiol.20131–147. 10.1023/A:1007074420772
2
Bailey E. L. Wardlaw J. M. Graham D. Dominiczak A. F. Sudlow C. L. Smith C. (2011). Cerebral small vessel endothelial structural changes predate hypertension in stroke-prone spontaneously hypertensive rats: A blinded, controlled immunohistochemical study of 5- to 21-week-old rats.Neuropathol. Appl. Neurobiol.37711–726. 10.1111/j.1365-2990.2011.01170.x
3
Bath P. M. Scutt P. Blackburn D. J. Ankolekar S. Krishnan K. Ballard C. et al (2017). Intensive versus guideline blood pressure and lipid lowering in patients with previous stroke: main results from the pilot ‘prevention of decline in cognition after stroke trial’ (PODCAST) Randomised controlled trial.PLoS One12:e0164608. 10.1371/journal.pone.0164608
4
Black S. Gao F. Bilbao J. (2009). Understanding white matter disease: Imaging-pathological correlations in vascular cognitive impairment.Stroke40S48–52. 10.1161/STROKEAHA.108.537704
5
Blair G. W. Appleton J. P. Flaherty K. Doubal F. Sprigg N. Dooley R. et al (2019). Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: The LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial.EClinicalMedicine1134–43. 10.1016/j.eclinm.2019.04.001
6
Bordes C. Sargurupremraj M. Mishra A. Debette S. (2022). Genetics of common cerebral small vessel disease.Nat. Rev. Neurol.1884–101. 10.1038/s41582-021-00592-8
7
Brundula V. Rewcastle N. B. Metz L. M. Bernard C. C. Yong V. W. (2002). Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis.Brain1251297–1308. 10.1093/brain/awf133
8
Cannistraro R. J. Badi M. Eidelman B. H. Dickson D. W. Middlebrooks E. H. Meschia J. F. (2019). CNS small vessel disease: A clinical review.Neurology921146–1156. 10.1212/WNL.0000000000007654
9
Choi P. Ren M. Phan T. G. Callisaya M. Ly J. V. Beare R. et al (2012). Silent infarcts and cerebral microbleeds modify the associations of white matter lesions with gait and postural stability: Population-based study.Stroke431505–1510. 10.1161/STROKEAHA.111.647271
10
Cipolla M. J. Liebeskind D. S. Chan S. L. (2018). The importance of comorbidities in ischemic stroke: Impact of hypertension on the cerebral circulation.J. Cereb. Blood Flow Metab.382129–2149. 10.1177/0271678X18800589
11
Craggs L. J. Hagel C. Kuhlenbaeumer G. Borjesson-Hanson A. Andersen O. Viitanen M. et al (2013). Quantitative vascular pathology and phenotyping familial and sporadic cerebral small vessel diseases.Brain Pathol.23547–557. 10.1111/bpa.12041
12
de Laat K. F. Tuladhar A. M. van Norden A. G. Norris D. G. Zwiers M. P. de Leeuw F. E. (2011). Loss of white matter integrity is associated with gait disorders in cerebral small vessel disease.Brain13473–83. 10.1093/brain/awq343
13
De Silva T. M. Faraci F. M. (2020). Contributions of aging to cerebral small vessel disease.Annu. Rev. Physiol.82275–295. 10.1146/annurev-physiol-021119-034338
14
De Silva T. M. Miller A. A. (2016). Cerebral small vessel disease: Targeting oxidative stress as a novel therapeutic strategy?.Front. Pharmacol.7:61. 10.3389/fphar.2016.00061
15
Debette S. Markus H. S. (2010). The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: Systematic review and meta-analysis.BMJ341:c3666. 10.1136/bmj.c3666
16
Dharmashankar K. Widlansky M. E. (2010). Vascular endothelial function and hypertension: Insights and directions.Curr. Hypertens. Rep.12448–455. 10.1007/s11906-010-0150-2
17
Dinan T. G. Cryan J. F. (2017). Gut instincts: Microbiota as a key regulator of brain development, ageing and neurodegeneration.J. Physiol.595489–503. 10.1113/JP273106
18
Durgan D. J. Lee J. McCullough L. D. Bryan R. M. Jr. (2019). Examining the role of the microbiota-gut-brain axis in stroke.Stroke502270–2277. 10.1161/STROKEAHA.119.025140
19
Edison P. (2021). Microglial activation and blood-brain barrier leakage: Chicken and egg?.Brain1441284–1285. 10.1093/brain/awab149
20
Evans L. E. Taylor J. L. Smith C. J. Pritchard H. A. T. Greenstein A. S. Allan S. M. (2021). Cardiovascular comorbidities, inflammation, and cerebral small vessel disease.Cardiovasc. Res.1172575–2588. 10.1093/cvr/cvab284
21
Feigin I. Popoff N. (1963). Neuropathological changes late in cerebral edema: The relationship to trauma, hypertensive disease and binswanger’s encephalopathy.J. Neuropathol. Exp. Neurol.22500–511. 10.1097/00005072-196307000-00011
22
Franceschi C. Bonafe M. Valensin S. Olivieri F. De Luca M. Ottaviani E. et al (2000). Inflamm-aging. An evolutionary perspective on immunosenescence.Ann. N. Y. Acad. Sci.908244–254. 10.1111/j.1749-6632.2000.tb06651.x
23
Friedland R. P. (2015). Mechanisms of molecular mimicry involving the microbiota in neurodegeneration.J. Alzheimers Dis.45349–362. 10.3233/JAD-142841
24
Frosen J. Joutel A. (2018). Smooth muscle cells of intracranial vessels: From development to disease.Cardiovasc. Res.114501–512. 10.1093/cvr/cvy002
25
Fu Y. Yan Y. (2018). Emerging role of immunity in cerebral small vessel disease.Front. Immunol.9:67. 10.3389/fimmu.2018.00067
26
Galatius S. Wroblewski H. Sorensen V. B. Bie P. Parving H. H. Kastrup J. (1999). Endothelin and von willebrand factor as parameters of endothelial function in idiopathic dilated cardiomyopathy: Different stimuli for release before and after heart transplantation?.Am. Heart J.137549–554. 10.1016/S0002-8703(99)70505-3
27
Gao F. Jing Y. Zang P. Hu X. Gu C. Wu R. et al (2019). Vascular cognitive impairment caused by cerebral small vessel disease is associated with the TLR4 in the hippocampus.J. Alzheimers Dis.70563–572. 10.3233/JAD-190240
28
Gheissari A. Meamar R. Abedini A. Roomizadeh P. Shafiei M. Samaninobandegani Z. et al (2018). Association of matrix metalloproteinase-2 and matrix metalloproteinase-9 with endothelial dysfunction, cardiovascular disease risk factors and thrombotic events in children with end-stage renal disease.Iran. J. Kidney Dis.12169–177.
29
Gorelick P. B. Scuteri A. Black S. E. Decarli C. Greenberg S. M. Iadecola C. et al (2011). Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the American heart association/American stroke association.Stroke422672–2713. 10.1161/STR.0b013e3182299496
30
Gouw A. A. Seewann A. van der Flier W. M. Barkhof F. Rozemuller A. M. Scheltens P. et al (2011). Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations.J. Neurol. Neurosurg. Psychiatry82126–135. 10.1136/jnnp.2009.204685
31
Gunarathne A. Patel J. V. Kausar S. Gammon B. Hughes E. A. Lip G. Y. (2009). Glycemic status underlies increased arterial stiffness and impaired endothelial function in migrant South Asian stroke survivors compared to European Caucasians: Pathophysiological insights from the West Birmingham Stroke Project.Stroke402298–2306. 10.1161/STROKEAHA.109.548388
32
Hainsworth A. H. Minett T. Andoh J. Forster G. Bhide I. Barrick T. R. et al (2017). Neuropathology of white matter lesions, blood-brain barrier dysfunction, and dementia.Stroke482799–2804. 10.1161/STROKEAHA.117.018101
33
Hainsworth A. H. Oommen A. T. Bridges L. R. (2015). Endothelial cells and human cerebral small vessel disease.Brain Pathol.2544–50. 10.1111/bpa.12224
34
Hartz A. M. Bauer B. Soldner E. L. Wolf A. Boy S. Backhaus R. et al (2012). Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy.Stroke43514–523. 10.1161/STROKEAHA.111.627562
35
Held F. Morris A. W. J. Pirici D. Niklass S. Sharp M. M. G. Garz C. et al (2017). Vascular basement membrane alterations and beta-amyloid accumulations in an animal model of cerebral small vessel disease.Clin. Sci.1311001–1013. 10.1042/CS20170004
36
Houde M. Desbiens L. D’Orleans-Juste P. (2016). Endothelin-1: Biosynthesis, signaling and vasoreactivity.Adv. Pharmacol.77143–175. 10.1016/bs.apha.2016.05.002
37
Hu X. De Silva T. M. Chen J. Faraci F. M. (2017). Cerebral vascular disease and neurovascular injury in ischemic stroke.Circ. Res.120449–471. 10.1161/CIRCRESAHA.116.308427
38
Huisa B. N. Caprihan A. Thompson J. Prestopnik J. Qualls C. R. Rosenberg G. A. (2015). Long-term blood-brain barrier permeability changes in binswanger disease.Stroke462413–2418. 10.1161/STROKEAHA.115.009589
39
Ihara M. Yamamoto Y. (2016). Emerging evidence for pathogenesis of sporadic cerebral small vessel disease.Stroke47554–560. 10.1161/STROKEAHA.115.009627
40
Jalal F. Y. Yang Y. Thompson J. Lopez A. C. Rosenberg G. A. (2012). Myelin loss associated with neuroinflammation in hypertensive rats.Stroke431115–1122. 10.1161/STROKEAHA.111.643080
41
Jalal F. Y. Yang Y. Thompson J. F. Roitbak T. Rosenberg G. A. (2015). Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP.J. Cereb. Blood Flow Metab.351145–1153. 10.1038/jcbfm.2015.21
42
Ji T. Zhao Y. Wang J. Cui Y. Duan D. Chai Q. et al (2018). Effect of low-dose statins and apolipoprotein E genotype on cerebral small vessel disease in older hypertensive patients: A subgroup analysis of a randomized clinical trial.J. Am. Med. Dir. Assoc.19995–1002.e4. 10.1016/j.jamda.2018.05.025
43
Jiang J. Yao K. Huang X. Zhang Y. Shen F. Weng S. (2022). Longitudinal white matter hyperintensity changes and cognitive decline in patients with minor stroke.Aging Clin. Exp. Res.341047–1054. 10.1007/s40520-021-02024-5
44
Jiang L. Cai X. Yao D. Jing J. Mei L. Yang Y. et al (2022). Association of inflammatory markers with cerebral small vessel disease in community-based population.J. Neuroinflammation19:106. 10.1186/s12974-022-02468-0
45
Kaiser D. Weise G. Moller K. Scheibe J. Posel C. Baasch S. et al (2014). Spontaneous white matter damage, cognitive decline and neuroinflammation in middle-aged hypertensive rats: An animal model of early-stage cerebral small vessel disease.Acta Neuropathol. Commun.2:169. 10.1186/s40478-014-0169-8
46
Kapasi A. DeCarli C. Schneider J. A. (2017). Impact of multiple pathologies on the threshold for clinically overt dementia.Acta Neuropathol.134171–186. 10.1007/s00401-017-1717-7
47
Karlsson F. H. Fak F. Nookaew I. Tremaroli V. Fagerberg B. Petranovic D. et al (2012). Symptomatic atherosclerosis is associated with an altered gut metagenome.Nat. Commun.3:1245. 10.1038/ncomms2266
48
Katusic Z. S. Austin S. A. (2014). Endothelial nitric oxide: Protector of a healthy mind.Eur. Heart J.35888–894. 10.1093/eurheartj/eht544
49
Kerkhofs D. van Hagen B. T. Milanova I. V. Schell K. J. van Essen H. Wijnands E. et al (2020). Pharmacological depletion of microglia and perivascular macrophages prevents Vascular Cognitive Impairment in Ang II-induced hypertension.Theranostics109512–9527. 10.7150/thno.44394
50
Kim Y. J. Kwon H. K. Lee J. M. Cho H. Kim H. J. Park H. K. et al (2016). Gray and white matter changes linking cerebral small vessel disease to gait disturbances.Neurology861199–1207. 10.1212/WNL.0000000000002516
51
Kitamura A. Manso Y. Duncombe J. Searcy J. Koudelka J. Binnie M. et al (2017). Long-term cilostazol treatment reduces gliovascular damage and memory impairment in a mouse model of chronic cerebral hypoperfusion.Sci. Rep.7:4299. 10.1038/s41598-017-04082-0
52
Kwok C. S. Shoamanesh A. Copley H. C. Myint P. K. Loke Y. K. Benavente O. R. (2015). Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: Pooled analysis of randomized trials.Stroke461014–1023. 10.1161/STROKEAHA.114.008422
53
Lammie G. A. (2002). Hypertensive cerebral small vessel disease and stroke.Brain Pathol.12358–370. 10.1111/j.1750-3639.2002.tb00450.x
54
Li C. C. Chen W. X. Wang J. Xia M. Jia Z. C. Guo C. et al (2020). Nicotinamide riboside rescues angiotensin II-induced cerebral small vessel disease in mice.CNS Neurosci. Ther.26438–447. 10.1111/cns.13276
55
Li Q. Yang Y. Reis C. Tao T. Li W. Li X. et al (2018). Cerebral small vessel disease.Cell Transplant.271711–1722. 10.1177/0963689718795148
56
Li S. Oh B. C. Chu C. Arnold A. Jablonska A. Furtmuller G. J. et al (2019). Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts.Brain1423456–3472. 10.1093/brain/awz275
57
Li T. Huang Y. Cai W. Chen X. Men X. Lu T. et al (2020). Age-related cerebral small vessel disease and inflammaging.Cell Death Dis.11:932. 10.1038/s41419-020-03137-x
58
Li Y. Li M. Zuo L. Shi Q. Qin W. Yang L. et al (2018). Compromised blood-brain barrier integrity is associated with total magnetic resonance imaging burden of cerebral small vessel disease.Front. Neurol.9:221. 10.3389/fneur.2018.00221
59
Liu N. Xue Y. Tang J. Zhang M. Ren X. Fu J. (2021). The dynamic change of phenotypic markers of smooth muscle cells in an animal model of cerebral small vessel disease.Microvasc. Res.133:104061. 10.1016/j.mvr.2020.104061
60
Loso J. Lund N. Avanesov M. Muschol N. Lezius S. Cordts K. et al (2018). Serum biomarkers of endothelial dysfunction in fabry associated cardiomyopathy.Front. Cardiovasc. Med.5:108. 10.3389/fcvm.2018.00108
61
Low A. Mak E. Rowe J. B. Markus H. S. O’Brien J. T. (2019). Inflammation and cerebral small vessel disease: A systematic review.Ageing Res. Rev.53:100916. 10.1016/j.arr.2019.100916
62
Makedonov I. Black S. E. MacIntosh B. J. (2013). Cerebral small vessel disease in aging and Alzheimer’s disease: A comparative study using MRI and SPECT.Eur. J. Neurol.20243–250. 10.1111/j.1468-1331.2012.03785.x
63
Markus H. S. Lythgoe D. J. Ostegaard L. O’Sullivan M. Williams S. C. (2000). Reduced cerebral blood flow in white matter in ischaemic leukoaraiosis demonstrated using quantitative exogenous contrast based perfusion MRI.J. Neurol. Neurosurg. Psychiatry6948–53. 10.1136/jnnp.69.1.48
64
Metz L. M. Li D. K. B. Traboulsee A. L. Duquette P. Eliasziw M. Cerchiaro G. et al (2017). Trial of minocycline in a clinically isolated syndrome of multiple sclerosis.N. Engl. J. Med.3762122–2133. 10.1056/NEJMoa1608889
65
Moody D. M. Brown W. R. Challa V. R. Ghazi-Birry H. S. Reboussin D. M. (1997). Cerebral microvascular alterations in aging, leukoaraiosis, and Alzheimer’s disease.Ann. N. Y. Acad. Sci.826103–116. 10.1111/j.1749-6632.1997.tb48464.x
66
Munoz Maniega S. Chappell F. M. Valdes Hernandez M. C. Armitage P. A. Makin S. D. Heye A. K. et al (2017). Integrity of normal-appearing white matter: Influence of age, visible lesion burden and hypertension in patients with small-vessel disease.J. Cereb. Blood Flow Metab.37644–656. 10.1177/0271678X16635657
67
Nakazaki M. Sasaki M. Kataoka-Sasaki Y. Oka S. Suzuki J. Sasaki Y. et al (2019). Intravenous infusion of mesenchymal stem cells improves impaired cognitive function in a cerebral small vessel disease model.Neuroscience408361–377. 10.1016/j.neuroscience.2019.04.018
68
Nelson J. W. Phillips S. C. Ganesh B. P. Petrosino J. F. Durgan D. J. Bryan R. M. (2021). The gut microbiome contributes to blood-brain barrier disruption in spontaneously hypertensive stroke prone rats.FASEB J.35:e21201. 10.1096/fj.202001117R
69
Nitta T. Hata M. Gotoh S. Seo Y. Sasaki H. Hashimoto N. et al (2003). Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice.J. Cell Biol.161653–660. 10.1083/jcb.200302070
70
O’Sullivan M. Lythgoe D. J. Pereira A. C. Summers P. E. Jarosz J. M. Williams S. C. et al (2002). Patterns of cerebral blood flow reduction in patients with ischemic leukoaraiosis.Neurology59321–326. 10.1212/WNL.59.3.321
71
Pantoni L. (2010). Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges.Lancet Neurol.9689–701. 10.1016/S1474-4422(10)70104-6
72
Park M. H. Lee J. Y. Park K. H. Jung I. K. Kim K. T. Lee Y. S. et al (2018). Vascular and neurogenic rejuvenation in aging mice by modulation of ASM.Neuron100167–182.e9. 10.1016/j.neuron.2018.09.010
73
Peters A. (2007). “The effects of normal aging on nerve fibers and neuroglia in the central nervous system,” in Brain Aging: Models, Methods, and Mechanisms, ed.RiddleD. R. (Boca Raton, FL: CRC Press). 10.1201/9781420005523-5
74
Petersen M. A. Ryu J. K. Akassoglou K. (2018). Fibrinogen in neurological diseases: Mechanisms, imaging and therapeutics.Nat. Rev. Neurosci.19283–301. 10.1038/nrn.2018.13
75
Petrie J. R. Guzik T. J. Touyz R. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms.Can. J. Cardiol.34575–584. 10.1016/j.cjca.2017.12.005
76
Piao J. Major T. Auyeung G. Policarpio E. Menon J. Droms L. et al (2015). Human embryonic stem cell-derived oligodendrocyte progenitors remyelinate the brain and rescue behavioral deficits following radiation.Cell Stem Cell16198–210. 10.1016/j.stem.2015.01.004
77
Poggesi A. Pasi M. Pescini F. Pantoni L. Inzitari D. (2016). Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review.J. Cereb. Blood Flow Metab.3672–94. 10.1038/jcbfm.2015.116
78
Promjunyakul N. O. Dodge H. H. Lahna D. Boespflug E. L. Kaye J. A. Rooney W. D. et al (2018). Baseline NAWM structural integrity and CBF predict periventricular WMH expansion over time.Neurology90e2119–e2126. 10.1212/WNL.0000000000005684
79
Quick S. Moss J. Rajani R. M. Williams A. (2021). A vessel for change: endothelial dysfunction in cerebral small vessel disease.Trends Neurosci.44289–305. 10.1016/j.tins.2020.11.003
80
Rajani R. M. Quick S. Ruigrok S. R. Graham D. Harris S. E. Verhaaren B. F. J. et al (2018). Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats.Sci. Transl. Med.10:eaam9507. 10.1126/scitranslmed.aam9507
81
Rajani R. M. Ratelade J. Domenga-Denier V. Hase Y. Kalimo H. Kalaria R. N. et al (2019). Blood brain barrier leakage is not a consistent feature of white matter lesions in CADASIL.Acta Neuropathol. Commun.7:187. 10.1186/s40478-019-0844-x
82
Righart R. Duering M. Gonik M. Jouvent E. Reyes S. Herve D. et al (2013). Impact of regional cortical and subcortical changes on processing speed in cerebral small vessel disease.Neuroimage Clin.2854–861. 10.1016/j.nicl.2013.06.006
83
Rouhl R. P. Damoiseaux J. G. Lodder J. Theunissen R. O. Knottnerus I. L. Staals J. et al (2012). Vascular inflammation in cerebral small vessel disease.Neurobiol. Aging331800–1806. 10.1016/j.neurobiolaging.2011.04.008
84
Sanchez-Rodriguez E. Egea-Zorrilla A. Plaza-Diaz J. Aragon-Vela J. Munoz-Quezada S. Tercedor-Sanchez L. et al (2020). The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases.Nutrients12:605. 10.3390/nu12030605
85
Schreiber S. Wilisch-Neumann A. Schreiber F. Assmann A. Scheumann V. Perosa V. et al (2020). Invited review: The spectrum of age-related small vessel diseases: Potential overlap and interactions of amyloid and nonamyloid vasculopathies.Neuropathol. Appl. Neurobiol.46219–239. 10.1111/nan.12576
86
Simpson J. E. Fernando M. S. Clark L. Ince P. G. Matthews F. Forster G. et al (2007). White matter lesions in an unselected cohort of the elderly: Astrocytic, microglial and oligodendrocyte precursor cell responses.Neuropathol. Appl. Neurobiol.33410–419. 10.1111/j.1365-2990.2007.00828.x
87
Sokolova I. B. Sergeev I. V. Skorobogataya E. V. Ufimtseva A. N. Polyntsev D. G. Dvoretskii D. P. (2017). Effect of transplantation of mesenchymal stem cells on the density of pial microvascular network in spontaneously hypertensive rats of different age.Bull. Exp. Biol. Med.163129–132. 10.1007/s10517-017-3752-8
88
Stamatovic S. M. Martinez-Revollar G. Hu A. Choi J. Keep R. F. Andjelkovic A. V. (2019). Decline in Sirtuin-1 expression and activity plays a critical role in blood-brain barrier permeability in aging.Neurobiol. Dis.126105–116. 10.1016/j.nbd.2018.09.006
89
Sun Z. Gao C. Gao D. Sun R. Li W. Wang F. et al (2021). Reduction in pericyte coverage leads to blood-brain barrier dysfunction via endothelial transcytosis following chronic cerebral hypoperfusion.Fluids Barriers CNS18:21. 10.1186/s12987-021-00255-2
90
Sweeney M. D. Sagare A. P. Zlokovic B. V. (2018). Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.Nat. Rev. Neurol.14133–150. 10.1038/nrneurol.2017.188
91
Tan C. Lu N. N. Wang C. K. Chen D. Y. Sun N. H. Lyu H. et al (2019). Endothelium-derived semaphorin 3G regulates hippocampal synaptic structure and plasticity via neuropilin-2/plexinA4.Neuron101920–937.e13. 10.1016/j.neuron.2018.12.036
92
Ter Telgte A. van Leijsen E. M. C. Wiegertjes K. Klijn C. J. M. Tuladhar A. M. de Leeuw F. E. (2018). Cerebral small vessel disease: From a focal to a global perspective.Nat. Rev. Neurol.14387–398. 10.1038/s41582-018-0014-y
93
Thal D. R. Ghebremedhin E. Orantes M. Wiestler O. D. (2003). Vascular pathology in Alzheimer disease: Correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline.J. Neuropathol. Exp. Neurol.621287–1301. 10.1093/jnen/62.12.1287
94
Tuladhar A. M. Reid A. T. Shumskaya E. de Laat K. F. van Norden A. G. van Dijk E. J. et al (2015). Relationship between white matter hyperintensities, cortical thickness, and cognition.Stroke46425–432. 10.1161/STROKEAHA.114.007146
95
van der Holst H. M. Tuladhar A. M. Zerbi V. van Uden I. W. M. de Laat K. F. van Leijsen E. M. C. et al (2018). White matter changes and gait decline in cerebral small vessel disease.Neuroimage Clin.17731–738. 10.1016/j.nicl.2017.12.007
96
van Middelaar T. Argillander T. E. Schreuder F. Deinum J. Richard E. Klijn C. J. M. (2018). Effect of antihypertensive medication on cerebral small vessel disease: A systematic review and meta-analysis.Stroke491531–1533. 10.1161/STROKEAHA.118.021160
97
Villamor E. Kessels C. G. Fischer M. A. Bast A. de Mey J. G. Blanco C. E. (2003). Role of superoxide anion on basal and stimulated nitric oxide activity in neonatal piglet pulmonary vessels.Pediatr. Res.54372–381. 10.1203/01.PDR.0000077481.15081.C8
98
Virdis A. Neves M. F. Amiri F. Touyz R. M. Schiffrin E. L. (2004). Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice.J. Hypertens.22535–542. 10.1097/00004872-200403000-00016
99
Vitale G. Salvioli S. Franceschi C. (2013). Oxidative stress and the ageing endocrine system.Nat. Rev. Endocrinol.9228–240. 10.1038/nrendo.2013.29
100
Walsh J. Tozer D. J. Sari H. Hong Y. T. Drazyk A. Williams G. et al (2021). Microglial activation and blood-brain barrier permeability in cerebral small vessel disease.Brain1441361–1371. 10.1093/brain/awab003
101
Wang R. Chu C. Wei Z. Chen L. Xu J. Liang Y. et al (2021). Traumatic brain injury does not disrupt costimulatory blockade-induced immunological tolerance to glial-restricted progenitor allografts.J. Neuroinflammation18:104. 10.1186/s12974-021-02152-9
102
Wang S. Liu J. Wu D. I. Pang X. Zhao J. Zhang X. (2015). Pro-inflammatory effect of fibrinogen on vascular smooth muscle cells by regulating the expression of PPARalpha, PPARgamma and MMP-9.Biomed. Rep.3513–518. 10.3892/br.2015.459
103
Wardlaw J. Bath P. M. W. Doubal F. Heye A. Sprigg N. Woodhouse L. J. et al (2020). Protocol: The Lacunar Intervention Trial 2 (LACI-2). A trial of two repurposed licenced drugs to prevent progression of cerebral small vessel disease.Eur. Stroke J.5297–308. 10.1177/2396987320920110
104
Wardlaw J. M. (2001). Prevalence of cerebral white matter lesions in elderly people: A population based magnetic resonance imaging study: The rotterdam scan study.J. Neurol. Neurosurg. Psychiatry702–3. 10.1136/jnnp.70.1.2
105
Wardlaw J. M. (2010). Blood-brain barrier and cerebral small vessel disease.J. Neurol. Sci.29966–71. 10.1016/j.jns.2010.08.042
106
Wardlaw J. M. Allerhand M. Doubal F. N. Valdes Hernandez M. Morris Z. Gow A. J. et al (2014). Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities.Neurology821331–1338. 10.1212/WNL.0000000000000312
107
Wardlaw J. M. Debette S. Jokinen H. De Leeuw F. E. Pantoni L. Chabriat H. et al (2021). ESO Guideline on covert cerebral small vessel disease.Eur. Stroke J.6:IV. 10.1177/23969873211027002
108
Wardlaw J. M. Doubal F. N. Valdes-Hernandez M. Wang X. Chappell F. M. Shuler K. et al (2013a). Blood-brain barrier permeability and long-term clinical and imaging outcomes in cerebral small vessel disease.Stroke44525–527. 10.1161/STROKEAHA.112.669994
109
Wardlaw J. M. Smith C. Dichgans M. (2013b). Mechanisms of sporadic cerebral small vessel disease: Insights from neuroimaging.Lancet Neurol.12483–497. 10.1016/S1474-4422(13)70060-7
110
Wardlaw J. M. Smith E. E. Biessels G. J. Cordonnier C. Fazekas F. Frayne R. et al (2013c). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.Lancet Neurol.12822–838. 10.1016/S1474-4422(13)70124-8
111
Wardlaw J. M. Makin S. J. Valdés Hernández M. C. Armitage P. A. Heye A. K. Chappell F. M. et al (2016). Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: Evidence from a cohort study.Alzheimers Dement.13634–643. 10.1016/j.jalz.2016.09.006
112
Wardlaw J. M. Sandercock P. A. Dennis M. S. Starr J. (2003). Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia?.Stroke34806–812. 10.1161/01.STR.0000058480.77236.B3
113
Wardlaw J. M. Smith C. Dichgans M. (2019). Small vessel disease: Mechanisms and clinical implications.Lancet Neurol.18684–696. 10.1016/S1474-4422(19)30079-1
114
Wharton S. B. Simpson J. E. Brayne C. Ince P. G. (2015). Age-associated white matter lesions: The MRC cognitive function and ageing study.Brain Pathol.2535–43. 10.1111/bpa.12219
115
Wong S. M. Jansen J. F. A. Zhang C. E. Hoff E. I. Staals J. van Oostenbrugge R. J. et al (2019). Blood-brain barrier impairment and hypoperfusion are linked in cerebral small vessel disease.Neurology92e1669–e1677. 10.1212/WNL.0000000000007263
116
Xiong Y. Wong A. Cavalieri M. Schmidt R. Chu W. W. Liu X. et al (2014). Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities.Neurotherapeutics11606–611. 10.1007/s13311-014-0270-5
117
Yang Y. Estrada E. Y. Thompson J. F. Liu W. Rosenberg G. A. (2007). Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat.J. Cereb. Blood Flow Metab.27697–709. 10.1038/sj.jcbfm.9600375
118
Yenari M. A. Xu L. Tang X. N. Qiao Y. Giffard R. G. (2006). Microglia potentiate damage to blood-brain barrier constituents: Improvement by minocycline in vivo and in vitro.Stroke371087–1093. 10.1161/01.STR.0000206281.77178.ac
119
Yong V. W. Power C. Forsyth P. Edwards D. R. (2001). Metalloproteinases in biology and pathology of the nervous system.Nat. Rev. Neurosci.2502–511. 10.1038/35081571
120
Zhang C. E. Wong S. M. van de Haar H. J. Staals J. Jansen J. F. Jeukens C. R. et al (2017). Blood-brain barrier leakage is more widespread in patients with cerebral small vessel disease.Neurology88426–432. 10.1212/WNL.0000000000003556
121
Zhang Y. Chen K. Sloan S. A. Bennett M. L. Scholze A. R. O’Keeffe S. et al (2014). An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex.J. Neurosci.3411929–11947. 10.1523/JNEUROSCI.1860-14.2014
122
Zhang Y. Zhang Y. Wu R. Gao F. Zang P. Hu X. et al (2019). Effect of cerebral small vessel disease on cognitive function and TLR4 expression in hippocampus.J. Clin. Neurosci.67210–214. 10.1016/j.jocn.2019.06.038
Summary
Keywords
cerebral small vessel disease, cognitive impairment, endothelial dysfunction, blood-brain barrier breakdown, white matter change, inflammation
Citation
Gao Y, Li D, Lin J, Thomas AM, Miao J, Chen D, Li S and Chu C (2022) Cerebral small vessel disease: Pathological mechanisms and potential therapeutic targets. Front. Aging Neurosci. 14:961661. doi: 10.3389/fnagi.2022.961661
Received
05 June 2022
Accepted
29 July 2022
Published
12 August 2022
Volume
14 - 2022
Edited by
Jenq-Lin Yang, Kaohsiung Chang Gung Memorial Hospital, Taiwan
Reviewed by
Mehmet Akif Topçuoğıu, Hacettepe University, Turkey; Siu-Lung Chan, Boston Children’s Hospital and Harvard Medical School, United States
Updates
Copyright
© 2022 Gao, Li, Lin, Thomas, Miao, Chen, Li and Chu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chengyan Chu, dychuchengyan@hotmail.com
This article was submitted to Neuroinflammation and Neuropathy, a section of the journal Frontiers in Aging Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.